• SPX
  • $5,966.93
  • 0.31 %
  • $18.22
  • DJI
  • $44,112.31
  • 0.55 %
  • $241.95
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,264.18
  • 1.41 %
  • $114.91
  • IXIC
  • $18,988.53
  • 0.08 %
  • $16.11
Connect Biopharma Holdings Limited (CNTB) Stock Price, News & Analysis

Connect Biopharma Holdings Limited (CNTB) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.02

$0.02

(2.51%)

Day's range
$1.02
Day's range
$1.04
50-day range
$0.911
Day's range
$1.52
  • Country: CN
  • ISIN: US2075231017
52 wk range
$0.68
Day's range
$2.66


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -2.05
  • Piotroski Score 5.00
  • Grade Buy
  • Symbol (CNTB)
  • Company Connect Biopharma Holdings Limited
  • Price $1.02
  • Changes Percentage (2.51%)
  • Change $0.02
  • Day Low $1.02
  • Day High $1.04
  • Year High $2.66

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/27/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $1.50
  • High Stock Price Target $1.50
  • Low Stock Price Target $1.50
  • Potential Upside/Downside N/A
  • Consensus Rating Buy
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.08
  • Trailing P/E Ratio -1.81
  • Forward P/E Ratio -1.81
  • P/E Growth -1.81
  • Net Income $-59,503,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Connect Biopharma Holdings Limited Frequently Asked Questions

  • What were the earnings of CNTB in the last quarter?

    In the last quarter Connect Biopharma Holdings Limited earnings were on Tuesday, September, 12th. The Connect Biopharma Holdings Limited maker reported -$0.08 EPS for the quarter, beating analysts' consensus estimates of -$6.92 by $6.84.

  • What is the Connect Biopharma Holdings Limited stock price today?

    Today's price of Connect Biopharma Holdings Limited is $1.02 — it has increased by +2.51% in the past 24 hours. Watch Connect Biopharma Holdings Limited stock price performance more closely on the chart.

  • Does Connect Biopharma Holdings Limited release reports?

    Yes, you can track Connect Biopharma Holdings Limited's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Connect Biopharma Holdings Limited stock forecast?

    Watch the Connect Biopharma Holdings Limited chart and read a more detailed Connect Biopharma Holdings Limited stock forecast to see what analysts suggest you do with its shares.

  • What is Connect Biopharma Holdings Limited stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Connect Biopharma Holdings Limited stock ticker.

  • How to buy Connect Biopharma Holdings Limited stocks?

    Like other stocks, CNTB shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Connect Biopharma Holdings Limited's EBITDA?

    Connect Biopharma Holdings Limited measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Connect Biopharma Holdings Limited’s financial statements.

  • What is the Connect Biopharma Holdings Limited's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Connect Biopharma Holdings Limited stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Connect Biopharma Holdings Limited's financials relevant news, and technical analysis. Connect Biopharma Holdings Limited's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Connect Biopharma Holdings Limited stock currently indicates a “sell” signal. For more insights, review Connect Biopharma Holdings Limited’s technical analysis.

  • A revenue figure for Connect Biopharma Holdings Limited for its last quarter?

    Connect Biopharma Holdings Limited published it's last quarterly revenues at $12.06 M.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.